| 1996 |
BCL7A was identified as a novel gene encoding a serine-rich protein of 231 amino acids with homology to the actin-binding protein caldesmon, discovered through molecular cloning of a three-way chromosomal translocation t(8;14;12) in a Burkitt lymphoma cell line where a MYC-BCL7A fusion transcript was produced with exon I of BCL7A replaced by MYC exon I. |
Molecular cloning, cDNA sequencing, Northern blot, sequence homology analysis |
Blood |
High |
8605326
|
| 1998 |
BCL7A defines a gene family (BCL7A, BCL7B, BCL7C) sharing ~90% identity in an amino-terminal domain of ~51 amino acids, with orthologs in Drosophila melanogaster, C. elegans, and Brugia malayi, but no identified protein motifs were found outside this conserved N-terminal domain. |
Sequence alignment, chromosomal mapping, EST homology analysis |
Gene |
Medium |
9931421
|
| 2017 |
BCL7A was identified as a subunit of the SWI/SNF complex in neurons; genetic deletion of BCL7A in postmitotic neurons in mice causes motor abnormalities and affects dendritic branching of Purkinje cells, while BCL7B knockout has no phenotype, demonstrating BCL7A's non-redundant role within SWI/SNF in neural function. |
Conditional and ubiquitous knockout mouse models, behavioral assays, neuronal morphology analysis |
Scientific reports |
High |
29213114
|
| 2020 |
BCL7A functions as a tumor suppressor in DLBCL by binding to the SWI/SNF complex via its amino-terminal domain; splice site mutations in intron 1 produce a truncated BCL7A protein that fails to bind the SWI/SNF complex and cannot suppress tumor growth, while restoration of wild-type BCL7A induces transcriptomic changes in B-cell activation genes. |
BCL7A restoration experiments, in vitro and in vivo tumor assays, splice site mutation analysis, SWI/SNF complex binding assays, transcriptome analysis |
Leukemia |
High |
32576963
|
| 2022 |
BCL7A modulates the SWI/SNF/BAF complex by stimulating genome-wide occupancy of the ATPase subunit BRG1; BCL7A is dispensable for SWI/SNF/BAF complex integrity but is essential for regulating Notch/Wnt pathway signaling and mitochondrial bioenergetics in differentiating neural progenitor cells (NPCs); pharmacological Wnt stimulation or mitochondrial biogenesis enhancement (pioglitazone) partially rescues BCL7A-deficient NPC phenotypes. |
BCL7A conditional knockout mice, genome-wide BRG1 occupancy (ChIP-seq), NPC differentiation assays, pharmacological rescue experiments, behavioral/cognitive testing |
The EMBO journal |
High |
36305367
|
| 2023 |
BCL7A expression is silenced in AML by promoter hypermethylation (confirmed by methylation-specific PCR, bisulfite sequencing, and 5-aza-2'-deoxycytidine treatment); restoration of BCL7A expression in AML cell lines reduces competitive growth, decreases tumor growth in xenograft models, and alters cell cycle pathways and expression of HMGCS1, H1-0, and IRF7. |
Methylation-specific PCR, bisulfite sequencing, 5-aza-2'-deoxycytidine treatment, cell competition assay, xenograft mouse model, differential expression analysis |
Biomarker research |
High |
36941700
|
| 2024 |
BCL7A acts as a tumor suppressor in AML and is negatively regulated post-transcriptionally by PTBP1; overexpression of BCL7A inhibits AML cell proliferation, induces apoptosis, promotes differentiation, and decreases cytarabine resistance by upregulating IRF7 and downregulating HMGCS1. |
BCL7A overexpression/knockdown in AML cell lines, in vivo mouse models, interaction studies with PTBP1, cell cycle/apoptosis/differentiation assays, IRF7/HMGCS1 expression analysis |
Drug resistance updates |
Medium |
39053383
|
| 2025 |
BCL7A directly interacts with the transcription factor IRF4 (plasma cell-defining), limiting its DNA-binding activity; loss of BCL7A in multiple myeloma cells enhances IRF4-associated cytokine expression, reduces mitochondrial metabolism and reactive oxygen species levels, and promotes cell proliferation, establishing BCL7A as a tumor suppressor in MM. |
Whole-genome sequencing, BCL7A loss-of-function and ectopic expression in MM cell lines, in vitro and in vivo proliferation assays, protein-protein interaction assay (BCL7A–IRF4 direct interaction), RNA-seq, metabolic assays |
Blood |
High |
40090008
|
| 2026 |
BCL7A contains a conserved arginine anchor in its N-terminal α-helix that is essential for chromatin remodeling activity of hSWI/SNF complexes; this anchor is required for BCL7A occupancy at target loci and chromatin accessibility/transcriptional regulation, but not for BCL7A integration into the complex; DLBCL-associated mutations in this anchor impair tumor suppressor function; mechanistically, BCL7A regulates histone displacement and works cooperatively with SMARCB1 to regulate canonical BAF (cBAF) remodeling activity. |
Protein structural prediction, mutagenesis of arginine anchor, in vivo and cellular tumor suppression assays, chromatin accessibility assays, transcriptional regulation analysis, ChIP occupancy assays |
Protein & cell |
High |
41485079
|
| 2025 |
BCL7 proteins (including BCL7A) act as dynamic molecular tethers within the SWI/SNF ARP module, connecting it to the nucleosomal acidic patch; BCL7 proteins promote ncBAF-mediated nucleosome remodeling, and BRG1-catalyzed ATP hydrolysis triggers conformational changes that modulate BCL7-mediated histone association, as resolved by cryo-EM of ncBAF-nucleosome complexes in nucleotide-free and nucleotide-bound states. (Note: this preprint describes BCL7B specifically, but establishes a general BCL7 family mechanism.) |
Cryo-electron microscopy, biochemical assays, cross-linking mass spectrometry, nucleosome remodeling assays |
bioRxivpreprint |
Medium |
bio_10.1101_2025.11.20.689410
|